Allen Morey, MD
Urology · Dallas, TXNPI 1972578755
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $552,103 of the $913,827 with a category attached, or 60.4%. Boston Scientific accounts for 74.6% of it on its own, with 23 other manufacturers making up the rest. Among urology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,268 payments — averaging $720.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$681K
- Coloplast$151K
- Laborie Medical Technologies Corp.$68K
- Endo USA, Inc.$12K
- Axonics, Inc.$389
- Johnson & Johnson$173
- plus $994 from 18 others
Across 14 payments — averaging $6983.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Laborie Medical Technologies Corp.$92K
- Coloplast$5K
- Urotronic, Inc$1K
What the payments were for
- Consulting fees$243,24327%
- Speaking & faculty fees$552,10360%
- Travel & lodging$64,9317%
- Food & beverage$34,0684%
- Education$19,4822%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 1,002 | $681,289 |
| Coloplast | 193 | $150,961 |
| Laborie Medical Technologies Corp. | 25 | $67,826 |
| Endo USA, Inc. | 13 | $12,196 |
| Axonics, Inc. | 6 | $389 |
| Johnson & Johnson | 2 | $173 |
| Astellas Pharma US Inc | 2 | $125 |
| Myovant Sciences Inc. | 1 | $118 |
| Valencia Technologies Corporation | 1 | $105 |
| Antares Pharma, Inc. | 2 | $100 |
| Merck | 1 | $87 |
| Rochester Medical Corporation | 4 | $78 |
| Sumitomo Pharma America, Inc. | 3 | $73 |
| Integra Lifesciences Corporation | 2 | $47 |
| Procept Biorobotics Corporation | 1 | $41 |
| Mimedx Group, Inc. | 2 | $40 |
| Novo Nordisk | 1 | $28 |
| Steris Corporation | 1 | $27 |
| LSI Solutions Inc | 1 | $27 |
| Dendreon Pharmaceuticals LLC | 1 | $26 |
| Davol Inc. | 1 | $25 |
| Olympus America Inc. | 1 | $17 |
| Pfizer | 1 | $15 |
| Biotissue Holdings Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TITAN$147,532
- GENERAL ERECTILE DYSFUNCTION$102,989
- AMS 700 CXR RTE KIT$73,775
- AdVance XP$72,240
- AMS$56,778
- TACTRA$39,802
- GENERAL - THERAPIES$39,206
- ADVANCE$36,463
- Optilume Urethral Drug Coated Balloon$33,292
- XIAFLEX$11,477
- AMS 700$9,425
- GENERAL VASCULAR ACCESS$4,500
- AMS 800 Artificial Urinary Sphincter$1,910
- GENERAL PAIN MANAGEMENT$992
- Axonics$257
- TOROSA$163
- Erleada$144
- GENERAL BPH$141
- GENERAL MALE SUI$131
- GENESIS$130
How this compares
$913,827 in reported general payments places this provider in the 95th percentile of 878 urology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 53 | $33,805 |
| Mirabegron ErMirabegron | 12 | $5,157 |
| Tamsulosin Hcl | 44 | $721 |
| Finasteride | 37 | $392 |
| Oxybutynin Chloride | 14 | $237 |
| Levofloxacin | 14 | $165 |
| Ciprofloxacin Hcl | 13 | $82 |
| Meloxicam | 16 | $65 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $125 | $33,80553 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 878 urology providers in Texas.
Other urology in Dallas
- Vitaly MargulisDallas$555K
- Yair LotanDallas$371K
- Claus RoehrbornDallas$169K
- Samantha NealonDallas$89K
- Maia VandykeDallas$79K
- Gary LemackDallas$62K
- Brian LangfordDallas$57K
- Jonathan SeamanDallas$55K
- Andrew von EschenbachMontgomery$3.2M
- Brian MazzarellaLakeway$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.